A detailed history of Pro Share Advisors LLC transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 23,854 shares of VYGR stock, worth $127,857. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,854
Holding current value
$127,857
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.77 - $9.27 $137,637 - $221,126
23,854 New
23,854 $139,000
Q1 2024

May 08, 2024

BUY
$7.15 - $10.84 $77,763 - $117,895
10,876 New
10,876 $101,000
Q2 2021

Aug 13, 2021

SELL
$3.94 - $5.44 $47,737 - $65,911
-12,116 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$4.61 - $9.04 $2,793 - $5,478
606 Added 5.26%
12,116 $57,000
Q4 2020

Feb 09, 2021

BUY
$7.15 - $12.28 $82,296 - $141,342
11,510 New
11,510 $82,000
Q1 2020

May 15, 2020

SELL
$6.8 - $14.66 $76,758 - $165,482
-11,288 Closed
0 $0
Q4 2019

Feb 12, 2020

SELL
$12.82 - $16.85 $18,730 - $24,617
-1,461 Reduced 11.46%
11,288 $157,000
Q3 2019

Nov 12, 2019

SELL
$16.31 - $28.29 $4,436 - $7,694
-272 Reduced 2.09%
12,749 $219,000
Q2 2019

Aug 13, 2019

SELL
$19.18 - $27.88 $7,518 - $10,928
-392 Reduced 2.92%
13,021 $354,000
Q1 2019

May 15, 2019

BUY
$8.0 - $19.66 $1,096 - $2,693
137 Added 1.03%
13,413 $257,000
Q4 2018

Feb 14, 2019

SELL
$8.59 - $18.05 $22,127 - $46,496
-2,576 Reduced 16.25%
13,276 $125,000
Q3 2018

Nov 14, 2018

SELL
$17.11 - $21.74 $9,530 - $12,109
-557 Reduced 3.39%
15,852 $300,000
Q2 2018

Aug 13, 2018

SELL
$16.76 - $23.92 $10,475 - $14,950
-625 Reduced 3.67%
16,409 $321,000
Q1 2018

May 14, 2018

SELL
$16.16 - $31.31 $45,312 - $87,793
-2,804 Reduced 14.13%
17,034 $320,000
Q4 2017

Feb 14, 2018

BUY
$12.26 - $25.88 $243,213 - $513,407
19,838
19,838 $329,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $207M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.